Advertisement

How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP)

      Highlights

      • No recommendations are available on switching disease-modifying treatments in multiple sclerosis
      • The French Multiple Sclerosis Society proposes guidelines on this important and practical topic

      Abstract

      Background

      Today, there are no recommendations on switching disease-modifying treatments (DMTs) in multiple sclerosis (MS).

      Objectives

      To establish guidelines on switching DMTs MS.

      Methods

      A Steering Committee composed of seven MS experts from the French Group for Recommendations in Multiple Sclerosis (France4MS) defined 15 proposals. These proposals were then submitted to a Rating Group, composed of 48 French MS experts, for evaluation. The proposals were classified as ‘appropriate’, ‘inappropriate’ or ‘uncertain’.

      Results

      Switching from a first-line therapy to another first-line therapy or a second-line therapy could be done without a washout period. Switching from a second-line therapy to a first-line therapy could be done without a washout period with fingolimod or natalizumab, after 3 months with ocrelizumab or mitoxantrone, and, if disease activity occurs with alemtuzumab or cladribine. The switch from a second-line therapy to another second-line therapy could be done after a washout period of 1 month with fingolimod or natalizumab, after 3 months with ocrelizumab, after 6 months with mitoxantrone, and, if disease activity occurs, with alemtuzumab or cladribine.

      Conclusion

      This expert consensus approach provides physicians with some guidelines on optimizing the benefit/risk ratio when switching DMTs in patients with MS.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Multiple Sclerosis and Related Disorders
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alcalá C.
        • Gascón F.
        • Pérez-Miralles F.
        • Domínguez J.A.
        • Gil-Perotín S.
        • Casanova B.
        Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe.
        J. Neurol. 2019; 266 (https://doi.org/): 726-734https://doi.org/10.1007/s00415-019-09195-2
        • Alping P.
        • Frisell T.
        • Novakova L.
        • Islam-Jakobsson P.
        • Salzer J.
        • Björck A.
        • Axelsson M.
        • Malmeström C.
        • Fink K.
        • Lycke J.
        • Svenningsson A.
        • Piehl F.
        Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.
        Ann. Neurol. 2016; 79 (https://doi.org/): 950-958https://doi.org/10.1002/ana.24651
        • Barry B.
        • Erwin A.A.
        • Stevens J.
        • Tornatore C.
        Fingolimod Rebound: A Review of the Clinical Experience and Management Considerations.
        Neurol Ther. 2019; 8 (https://doi.org/): 241-250https://doi.org/10.1007/s40120-019-00160-9
        • Calabrese M.
        • Pitteri M.
        • Farina G.
        • Bajrami A.
        • Castellaro M.
        • Magliozzi R.
        • Monaco S.
        Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
        J. Neurol. Neurosurg. Psychiatry. 2017; 88 (https://doi.org/): 1073-1078https://doi.org/10.1136/jnnp-2017-316236
        • Chan A.
        • Rose J.
        • Alvarez E.
        • Bar-Or A.
        • Butzkueven H.
        • Fox R.J.
        • Gold R.
        • Gudesblatt M.
        • Haartsen J.
        • Spelman T.
        • Wright K.
        • Ferraro D.
        • Sola P.
        • Hodgkinson S.
        • Kalincik T.
        • Lechner-Scott J.
        • McGuigan C.
        • Spach K.
        • Chen C.
        • Fam S.
        • Wu F.
        • Miller C.
        Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.
        Neurology: Clinical Practice. 2020; 10 (https://doi.org/): 510-519https://doi.org/10.1212/CPJ.0000000000000800
        • Cohan S.L.
        • Moses H.
        • Calkwood J.
        • Tornatore C.
        • LaGanke C.
        • Smoot K.E.
        • Meka V.
        • Okwuokenye M.
        • Hotermans C.
        • Mendoza J.P.
        • Mann M.K.
        • Meltzer L.A.
        Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
        Mult. Scler. Relat. Disord. 2018; 22 (https://doi.org/): 27-34https://doi.org/10.1016/j.msard.2018.02.028
        • Cohen M.
        • Maillart E.
        • Tourbah A.
        • De Sèze J.
        • Vukusic S.
        • Brassat D.
        • Anne O.
        • Wiertlewski S.
        • Camu W.
        • Courtois S.
        • Ruet A.
        • Debouverie M.
        • Le Page E.
        • Casez O.
        • Heinzlef O.
        • Stankoff B.
        • Bourre B.
        • Castelnovo G.
        • Rico A.
        • Berger E.
        • Camdessanche J.-P.
        • Defer G.
        • Clavelou P.
        • Al Khedr A.
        • Zephir H.
        • Fromont A.
        • Papeix C.
        • Brochet B.
        • Pelletier J.
        • Lebrun C.
        • Club Francophone de la Sclérose en Plaques Investigators
        Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study.
        JAMA Neurol. 2014; 71 (https://doi.org/): 436-441https://doi.org/10.1001/jamaneurol.2013.6240
        • Coss-Rovirosa F.
        • Salado-Burbano J.
        • Casallas-Vanegas A.
        • Caire-Herrera L.E.
        • Gómez-Figueroa E.
        • Flores-Rivera J.
        Severe fingolimod rebound syndrome after switching to cladribine treatment.
        Mult. Scler. Relat. Disord. 2020; 40 (https://doi.org/)101938https://doi.org/10.1016/j.msard.2020.101938
        • Fazekas F.
        • Bajenaru O.
        • Berger T.
        • Hojs Fabjan T.
        • Horvat Ledinek A.
        • Jakab G.
        • Komoly S.
        • Kobys T.
        • Kraus J.
        • Kurča E.
        • Kyriakides T.
        • Lisý L.
        • Milanov I.
        • Moskovko S.
        • Nehrych T.
        • Panayiotou P.
        • Sega Jazbec S.
        • Sokolova L.
        • Talab R.
        • Traykov L.
        • Turčáni P.
        • Vass K.
        • Vella N.
        • Voloshyna N.
        • Havrdova E.
        How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?.
        Front. Neurol. 2013; 4 (https://doi.org/)https://doi.org/10.3389/fneur.2013.00010
        • Fernández O.
        • Delvecchio M.
        • Edan G.
        • Fredrikson S.
        • Gionvannoni G.
        • Hartung H.-P.
        • Havrdova E.
        • Kappos L.
        • Pozzilli C.
        • Soerensen P.S.
        • Tackenberg B.
        • Vermersch P.
        • Comi G.
        Survey of diagnostic and treatment practices for multiple sclerosis in Europe.
        Eur. J. Neurol. 2017; 24 (https://doi.org/): 516-522https://doi.org/10.1111/ene.13236
        • Fox R.J.
        • Cree B.A.C.
        • De Sèze J.
        • Gold R.
        • Hartung H.-P.
        • Jeffery D.
        • Kappos L.
        • Kaufman M.
        • Montalbán X.
        • Weinstock-Guttman B.
        • Anderson B.
        • Natarajan A.
        • Ticho B.
        • Duda P.
        • RESTORE
        MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
        Neurology. 2014; 82 (https://doi.org/): 1491-1498https://doi.org/10.1212/WNL.0000000000000355
        • Frau J.
        • Sormani M.P.
        • Signori A.
        • Realmuto S.
        • Baroncini D.
        • Annovazzi P.
        • Signoriello E.
        • Maniscalco G.T.
        • La Gioia S.
        • Cordioli C.
        • Frigeni B.
        • Rasia S.
        • Fenu G.
        • Grasso R.
        • Sartori A.
        • Lanzillo R.
        • Stromillo M.L.
        • Rossi S.
        • Forci B.
        • Cocco E.
        • i-MuST study group
        Clinical activity after fingolimod cessation: disease reactivation or rebound?.
        Eur. J. Neurol. 2018; 25 (https://doi.org/): 1270-1275https://doi.org/10.1111/ene.13694
        • Holmøy T.
        • Torkildsen Ø.
        • Zarnovicky S.
        Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab.
        Case Rep Neurol Med. 2018; 2018 (https://doi.org/)5190794https://doi.org/10.1155/2018/5190794
        • Huhn K.
        • Bayas A.
        • Doerck S.
        • Frank B.
        • Gerbershagen K.
        • Hellwig K.
        • Kallmann B.
        • Kleinschnitz C.
        • Kleiter I.
        • Lee D.-H.
        • Limmroth V.
        • Mäurer M.
        • Meuth S.
        • Rieckmann P.
        • Ruck T.
        • Gold R.
        • Linker R.A.
        Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.
        J. Neurol. 2018; 265 (https://doi.org/): 1521-1527https://doi.org/10.1007/s00415-018-8871-2
        • John N.
        • Carroll A.
        • Brownlee W.J.
        • Chataway J.
        Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis.
        J. Neurol. Neurosurg. Psychiatry. 2019; 90 (https://doi.org/): 1376-1378https://doi.org/10.1136/jnnp-2019-320687
        • Leurs C.E.
        • van Kempen Z.L.
        • Dekker I.
        • Balk L.J.
        • Wattjes M.P.
        • Rispens T.
        • Uitdehaag B.M.
        • Killestein J.
        Switching natalizumab to fingolimod within 6 weeks reduces recurrence of disease activity in MS patients.
        Mult. Scler. 2018; 24 (https://doi.org/): 1453-1460https://doi.org/10.1177/1352458517726381
        • Levin S.N.
        • Ezuma C.
        • Levine L.
        • Vargas W.S.
        • Farber R.S.
        • De Jager P.L.
        • Riley C.S.
        Switching from natalizumab to ocrelizumab in patients with multiple sclerosis.
        Mult. Scler. 2020; 26 (https://doi.org/): 1964-1965https://doi.org/10.1177/1352458520927631
        • Lublin F.D.
        • Cofield S.S.
        • Cutter G.R.
        • Conwit R.
        • Narayana P.A.
        • Nelson F.
        • Salter A.R.
        • Gustafson T.
        • Wolinsky J.S.
        • CombiRx Investigators
        Randomized study combining interferon and glatiramer acetate in multiple sclerosis.
        Ann. Neurol. 2013; 73 (https://doi.org/): 327-340https://doi.org/10.1002/ana.23863
        • Luna G.
        • Alping P.
        • Burman J.
        • Fink K.
        • Fogdell-Hahn A.
        • Gunnarsson M.
        • Hillert J.
        • Langer-Gould A.
        • Lycke J.
        • Nilsson P.
        • Salzer J.
        • Svenningsson A.
        • Vrethem M.
        • Olsson T.
        • Piehl F.
        • Frisell T.
        Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.
        JAMA Neurol. 2020; 77: 184-191https://doi.org/10.1001/jamaneurol.2019.3365
        • Malucchi S.
        • Capobianco M.
        • Lo Re M.
        • Malentacchi M.
        • di Sapio A.
        • Matta M.
        • Sperli F.
        • Bertolotto A.
        High-Risk PML Patients Switching from Natalizumab to Alemtuzumab: an Observational Study.
        Neurol Ther. 2017; 6 (https://doi.org/): 145-152https://doi.org/10.1007/s40120-016-0058-0
        • Mancinelli C.R.
        • Scarpazza C.
        • Cordioli C.
        • De Rossi N.
        • Rasia S.
        • Turrini M.V.
        • Capra R.
        Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumab.
        Mult. Scler. 2020; (1352458520946017https://doi.org/)https://doi.org/10.1177/1352458520946017
        • Möhn N.
        • Skripuletz T.
        • Sühs K.-W.
        • Menck S.
        • Voß E.
        • Stangel M.
        Therapy with cladribine is efficient and safe in patients previously treated with natalizumab.
        Ther Adv Neurol Disord. 2019; 12 (1756286419887596https://doi.org/)https://doi.org/10.1177/1756286419887596
        • Montalban X.
        • Gold R.
        • Thompson A.J.
        • Otero-Romero S.
        • Amato M.P.
        • Chandraratna D.
        • Clanet M.
        • Comi G.
        • Derfuss T.
        • Fazekas F.
        • Hartung H.P.
        • Havrdova E.
        • Hemmer B.
        • Kappos L.
        • Liblau R.
        • Lubetzki C.
        • Marcus E.
        • Miller D.H.
        • Olsson T.
        • Pilling S.
        • Selmaj K.
        • Siva A.
        • Sorensen P.S.
        • Sormani M.P.
        • Thalheim C.
        • Wiendl H.
        • Zipp F.
        ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis.
        Mult. Scler. 2018; 24 (https://doi.org/): 96-120https://doi.org/10.1177/1352458517751049
        • Rae-Grant A.
        • Day G.S.
        • Marrie R.A.
        • Rabinstein A.
        • Cree B.A.C.
        • Gronseth G.S.
        • Haboubi M.
        • Halper J.
        • Hosey J.P.
        • Jones D.E.
        • Lisak R.
        • Pelletier D.
        • Potrebic S.
        • Sitcov C.
        • Sommers R.
        • Stachowiak J.
        • Getchius T.S.D.
        • Merillat S.A.
        • Pringsheim T.
        Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.
        Neurology. 2018; 90 (https://doi.org/): 777-788https://doi.org/10.1212/WNL.0000000000005347
        • Razaz N.
        • Piehl F.
        • Frisell T.
        • Langer-Gould A.M.
        • McKay K.A.
        • Fink K.
        Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab.
        Neurol Neuroimmunol Neuroinflamm. 2020; 7 (https://doi.org/)https://doi.org/10.1212/NXI.0000000000000903
        • Reich D.S.
        • Lucchinetti C.F.
        • Calabresi P.A.
        Multiple Sclerosis.
        N. Engl. J. Med. 2018; 378 (https://doi.org/): 169-180https://doi.org/10.1056/NEJMra1401483
        • Rudick R.A.
        • Stuart W.H.
        • Calabresi P.A.
        • Confavreux C.
        • Galetta S.L.
        • Radue E.-W.
        • Lublin F.D.
        • Weinstock-Guttman B.
        • Wynn D.R.
        • Lynn F.
        • Panzara M.A.
        • Sandrock A.W.
        Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis.
        New England Journal of Medicine. 2006; 354 (https://doi.org/): 911-923https://doi.org/10.1056/NEJMoa044396
        • Saccà F.
        • Lanzillo R.
        • Signori A.
        • Maniscalco G.T.
        • Signoriello E.
        • Lo Fermo S.
        • Repice A.
        • Annovazzi P.
        • Baroncini D.
        • Clerico M.
        • Binello E.
        • Cerqua R.
        • Mataluni G.
        • Bonavita S.
        • Lavorgna L.
        • Zarbo I.R.
        • Laroni A.
        • Rossi S.
        • Pareja Gutierrez L.
        • La Gioia S.
        • Frigeni B.
        • Barcella V.
        • Frau J.
        • Cocco E.
        • Fenu G.
        • Torri Clerici V.
        • Sartori A.
        • Rasia S.
        • Cordioli C.
        • Di Sapio A.
        • Pontecorvo S.
        • Grasso R.
        • Barrilà C.
        • Russo C.V.
        • Esposito S.
        • Ippolito D.
        • Bovis F.
        • Gallo F.
        • Sormani M.P.
        Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.
        Mult. Scler. 2019; 25 (https://doi.org/): 1263-1272https://doi.org/10.1177/1352458518790390
        • Schmidt S.
        • Schulten T.
        Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases.
        Ther Adv Neurol Disord. 2019; 12 (1756286419846818https://doi.org/)https://doi.org/10.1177/1756286419846818
        • Sellner J.
        • Rommer P.S.
        A review of the evidence for a natalizumab exit strategy for patients with multiple sclerosis.
        Autoimmun. Rev. 2019; 18 (https://doi.org/): 255-261https://doi.org/10.1016/j.autrev.2018.09.012
        • Tintore M.
        • Vidal-Jordana A.
        • Sastre-Garriga J.
        Treatment of multiple sclerosis — success from bench to bedside.
        Nature Reviews Neurology. 2019; 15 (https://doi.org/): 53https://doi.org/10.1038/s41582-018-0082-z
        • Vollmer B.
        • Honce J.M.
        • Sillau S.
        • Corboy J.R.
        • Vollmer T.
        • Nair K.
        • Alvarez E.
        The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis.
        J. Neurol. Sci. 2018; 390 (https://doi.org/): 89-93https://doi.org/10.1016/j.jns.2018.04.021
        • Wiese M.D.
        • Rowland A.
        • Polasek T.M.
        • Sorich M.J.
        • O’Doherty C.
        Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
        Expert Opin. Drug Metab. Toxicol. 2013; 9 (https://doi.org/): 1025-1035https://doi.org/10.1517/17425255.2013.800483
        • Willis M.
        • Pearson O.
        • Illes Z.
        • Sejbaek T.
        • Nielsen C.
        • Duddy M.
        • Petheram K.
        • van Munster C.
        • Killestein J.
        • Malmeström C.
        • Tallantyre E.
        • Robertson N.
        An observational study of alemtuzumab following fingolimod for multiple sclerosis.
        Neurol Neuroimmunol Neuroinflamm. 2017; 4 (https://doi.org/): e320https://doi.org/10.1212/NXI.0000000000000320
        • Winkelmann A.
        • Loebermann M.
        • Reisinger E.C.
        • Hartung H.-P.
        • Zettl U.K.
        Disease-modifying therapies and infectious risks in multiple sclerosis.
        Nat. Rev. Neurol. 2016; 12 (https://doi.org/): 217-233https://doi.org/10.1038/nrneurol.2016.21